Company profile
LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACECLIDINE HYDROCHLORIDE | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03201562 | phase2 | completed | 2017-04-30 | 2018-05-20 | LENZ Therapeutics, Inc | A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia |
| NCT02554396 | phase2 | completed | 2015-09-01 | 2015-11-01 | LENZ Therapeutics, Inc | Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia |
| NCT05431543 | phase2 | completed | 2022-08-06 | 2022-12-14 | LENZ Therapeutics, Inc | Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia |
| NCT05294328 | phase2 | completed | 2022-05-05 | 2022-08-22 | LENZ Therapeutics, Inc | Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia |
| NCT05728944 | phase3 | completed | 2023-03-06 | 2023-12-14 | LENZ Therapeutics, Inc | Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 218585 | NDA | LENZ THERAPEUTICS INC | ||||
Loading… | ||||||